SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro

Cancer Research

Volumn 63, Issue 13, 2003, Pages 3755-3763

  Abdollahi, Amir ^a,d   Lipson, Kenneth E ^b   Han, Xiaohong ^d   Krempien, Robert ^d   Trinh, Thuy ^d   Weber, Klaus J ^d   Hahnfeldt, Philip ^c   Hlatky, Lynn ^c   Debus, Juergen ^a,d   Howlett, Anthony R ^b   Huber, Peter E ^a,d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b SUGEN INC   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SEMAXANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER RADIOTHERAPY; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL; PROSTATE CANCER;

ANGIOGENESIS INHIBITORS; CELL DIVISION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; HUMANS; INDOLES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KINETICS; LYMPHOKINES; MALE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PARTICLE ACCELERATORS; PROSTATIC NEOPLASMS; PYRROLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; X-RAYS;

EID: 0038756364     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Carmeliet, P., and Jain, R. K. Angiogenesis in cancer and other diseases. Nature (Lond.), 407: 249-257, 2000.
2. Folkman, J., Hahnfeldt, P., and Hlatky, L. Cancer: looking outside the genome. Nat. Rev., 1: 76-79, 2000.
3. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.
4. Fong, T. A. T., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T. J., Kim, Y. H., Schreck, R., Wang, X., Risau, W., Ullrich, A., Hirth, K. P., and McMahon, G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res., 59: 99-106, 1999.
5. Laird, A. D., Vajkoczy, P., Laura, K. Shawver, L. K., Thumher, A., Liang, C., Mohammadi, M., Schlessinger, J., Ullrich, A., Hubbard, S. R., Blake, R. A., Fong, T. A. T., Strawn, L. M., Sun, L., Tang, C., Hawtin, R., Tang, F., Shenoy, N., Hirth, K. P., McMahon, G., and Cherrington, J. M. SU6668 is a potent antiangiogenetic and antitumor agent that induces regression of established tumors. Cancer Res., 60: 4152-4160, 2000.
6. Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., and Kerbel, R. S. Continuous low-dose therapy with vinblastine and VEGF receptor-2antibody induces sustained tumor regression without overt toxicity. J. Clin. Investig., 105: R15-R24, 2000.
7. Browder, T., Butterfield, C. E., Kraling, B. M., Shi, B., Marshall, B., O'Reilly, M. S., and Folkman, J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res., 60: 1878-1886, 2000.
8. Hahnfeldt, P., Folkman, J., and Hlatky, L. Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J. Theor. Biol., 220: 545-554, 2003.
9. Paris, F., Fuks, Z., Kang, A., Capodieci, P., Juan, G., Ehleiter, D., Haimovitz-Friedman, A., Cordon-Cardo, A., and Kolesnick, R. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science (Wash. DC), 293: 293-297, 2001.
10. Okunieff, P., Mester, M., Wang, J., Maddox, T., Gong, X., Tang, D., Coffee, M., and Ding, I. In vivo radioprotective effects of angiogenic growth factors on the small bowel of C3H mice. Radiat Res., 150: 204-211, 1998.
11. Gorski, D. H., Beckett, M. A., Jaskowiak, N. T., Calvin, D. P., Mauceri, H. J., Salloum, R. M., Seetharam, S., Koons, A., Hari, D. M., Kufe, D. W., and Weichselbaum, R. R. Blockade of vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res., 59: 3374-3378, 1999.
12. Fuks, Z., Persaud, R. S., Alfieri, A., McLoughlin, M., Ehleiter, D., Schwartz, J. L., Seddon, A. P., Cordon-Cardo, C., and Haimovitz-Friedman, A. Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res., 54: 2582-2590, 1994.
13. Folkman, J., and Camphausen, K. Cancer. What does radiotherapy do to endothelial cells? Science, 293: 227-228, 2001.
14. Neufeld, G., Cohen, T., Gengrinovitch, S., and Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J., 13: 9-22, 1999.
15. Valter, M., Hugel, A., Huang, S., Cavenee, W., Wiestler, O., Pietsch, T., and Wernert, N. Expression of the Ets-1 transcription factor in human astrocytomas is associated with Fms-like tyrosine kinase-1 (Flt-1)/vascular endothelial growth factor receptor-1 synthesis and neoangiogenesis. Cancer Res., 59: 5608-5614, 1999.
16. Pena, L. A., Fuks, Z., and Kolesnick, R. N. Radiation-induced apoptosis of endothelial cells in the murine central nervous system: protection by fibroblast growth factor and sphingomyelinase deficiency. Cancer Res., 60: 321-327, 2000.
17. Mauceri, H. J., Hanna, N. N., Beckett, M. A., Gorski, D. H., Staba, M., Stellato, K., Biglow, K., Heimann, R., Gately, S., Dhanabal, M., Soff, G. A., Sukhatme, V. P., Kufe, D. W., and Weichselbaum, R. R. Combined effects of angiostatin and ionizing radiation in antitumor therapy. Nature (Lond.), 394: 287-291, 1998.
18. Lee, C. G., Heijn, M., di Tomaso, E., Griffon-Etienne, G., Ancukiewicz, M., Koike, C., Park, K. R., Ferrara, N., Jain, R. K., Suit, H. D., and Boucher, Y. Anti-VEGF treatments augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res., 60: 5565-5570, 2000.
19. Kozin, S. V., Boucher, Y., Hicklin, D. J., Bohlen, P., Jain, R. K., and Suit, H. D. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res., 61: 39-44. 2001.
20. Geng, L., Donnelly, E., McMahon, G., Lin, P. C., Sierra-Rivera, E., Oshinka, H., and Hallahan, D. E. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res, 61: 2413-2419, 2001.
21. Hess, C., Vuong, V., Hegyi, I., Riesterer, O., Wood, J., Fabbro, D., Glanzmann, C., Bodis, S., and Pruschky, M. Effect of VEGF receptor inhibitor PTK787/ZK22258 combined with ionizing radiation on endothelial cells and tumour growth. Br. J. Cancer, 85: 2010-2016, 2001.
22. Dicker. A. P., Anne, R., Bonanni, R., Sidor, C., Gubish, E., and Curran, W. J., Jr. Phase I trial results of recombinant human angiostatin protein (rhA) and external beam radiation therapy (EBRT). Am. Soc. Clin. Oncol., Abstract No. 23, 2002.
23. Houchen, C. W., George, R. J., Sturmoski, M. A., and Cohn, S. M. FGF-2 enhances intestinal stem cell survival and its expression is induced after radiation injury. Am. J. Physiol., 276: G249-G258, 1999.
24. Gerber, H. P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V., and Ferrara, N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidyl-inositol 3-kinase/Akt signal transduction pathway. J. Biol. Chem., 273: 30336-30343, 1998.
25. Seftor, R. E. B. Role of the β3 integrin subunit in human primary melanoma progression. Multifunctional activities associated with avb3 integrin expression. Am. J. Pathol., 153: 1347-1351, 1998.
26. Hendry, J. H., and West, C. M. Apoptosis and mitotic cell death: their relative contributions to normal tissue and tumour-radiation response. Int. J. Radiat. Biol., 71: 709-719, 1997.
27. Zachary, I., Mathur, A., Yla-Herttuala, S., and Martin, J. F. Vascular protection: a novel, non-angiogenic cardiovascular role for vascular endothelial growth factor. Arterioscler. Thromb. Vasc. Biol., 20: 1512-1520, 2000.
28. Wild-Bode, C., Weller, M., Rimner, A., Dichgans, J., and Wick, W. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res., 61: 2744-2750, 2001.
29. Fertil, B., and Malaise, E. P. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int. J. Radiat. Oncol. Biol. Phys., 11: 1699-1707, 1985.
30. Hlatky, L., Hahnfeldt, P., Tsionou, C., and Coleman, C. N. Vascular endothelial growth factor: environmental controls and effects in angiogenesis. Br. J. Cancer, 74 (Suppl. XXVII): S151-S156, 1996.